Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC).
Otolaryngol Head Neck Surg
; 137(5): 722-8, 2007 Nov.
Article
in En
| MEDLINE
| ID: mdl-17967635
ABSTRACT
OBJECTIVE:
To determine if epigenetic-modifying drugs can increase iodine uptake in thyroid carcinoma cell lines. STUDYDESIGN:
Human thyroid carcinoma cell lines were tested for iodine uptake before and after treatment with epigenetic-modifying agents.RESULTS:
Thyroid carcinoma cell lines DRO and 2-7 had high levels of DNA methylation (74% and 80%) compared with normal thyroid tissue (6%) (P < 0.05). This finding correlated with low levels of sodium iodide symporter (NIS) expression in the untreated thyroid carcinoma cell line. Combination treatment with the epigenetic-modifying agents 5-aza-2'-deoxycytidine and sodium butyrate resulted in increases in NIS messenger RNA levels, global histone acetylation, and 9- and 8-fold increases in I(125) uptake for the DRO and 2-7 cells, respectively.CONCLUSIONS:
Epigenetic-modifier drugs represent a novel adjuvant treatment for those patients with radioablation-resistant thyroid cancer.SIGNIFICANCE:
Epigenetic-modifying agents show potential for treatment of radioablation-resistant thyroid cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Azacitidine
/
Butyrates
/
Thyroid Neoplasms
/
Epigenesis, Genetic
/
Iodine Radioisotopes
Limits:
Humans
Language:
En
Journal:
Otolaryngol Head Neck Surg
Year:
2007
Document type:
Article
Affiliation country:
Estados Unidos